Diabetes & Endocrinology
Latest news
531 articles · 20 / page
Intermittent Calorie Restriction: A Promising Dietary Strategy for Metabolic Dysfunction-Associated Steatotic Liver Disease
Recent trials show intermittent calorie restriction (ICR) significantly reduces liver fat content in MASLD and NAFLD, especially in obese patients, offering an effective and well-tolerated alternative to conventional diets.
Flaxseed Powder Supplementation: Emerging Evidence in Non-Alcoholic Fatty Liver Disease and Metabolic Health
Flaxseed powder supplementation shows promise in improving liver fat, lipid metabolism, and inflammation in NAFLD and related metabolic disorders, with effects on gut microbiota but limited synergism with fasting mimicking diets.
The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
This clinical trial evaluates chitosan supplementation’s impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.
Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial
A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timin
Time-Restricted Eating in Type 2 Diabetes: Can a Shorter Eating Window Boost β-Cell Function and Metabolic Health?
Recent trials suggest that time-restricted eating (TRE) may modestly improve β-cell function and metabolic control in type 2 diabetes, but effects on insulin sensitivity and long-term outcomes remain uncertain.
Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial
A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.
Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management
Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.
Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter
Akkermansia muciniphila supplementation improves metabolic outcomes in overweight/obese type 2 diabetes patients only when baseline gut levels are low, underscoring the need for personalized microbiota-guided interventions.
Unveiling the Link Between Low-Dose Cadmium Exposure and Gestational Diabetes Mellitus: Mechanistic Insights from Placental Models
Low-dose cadmium exposure during early pregnancy is strongly associated with increased risk of gestational diabetes mellitus, likely via placental metabolic and hormonal alterations.
Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial
Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.
How Should Diabetic Patients Eat Fruits?
Guidance on fruit consumption for diabetic patients, focusing on fruit types, portion control, timing, and blood sugar monitoring to maintain stable glucose levels.
How Should Diabetic Patients Consume Fruits?
This article guides diabetic patients on choosing appropriate fruits based on glycemic index and load, portion control, timing, and blood sugar monitoring for optimal health management.
Uncommon Weight-Loss Practices That Actually Work
Discover six surprising behaviors that can promote weight loss, including eating meat, healthy snacking, and proper sleep, all backed by science.
Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance
New GRADE sub-study reveals that somatic symptoms of depression, not cognitive-affective symptoms, are chiefly associated with inflammation and insulin resistance in type 2 diabetes, highlighting a pathophysiological bridge for targeted int
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland
The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.
Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial
The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.
Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective
Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.
Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction
Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.
Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials
Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.
Browse by specialty
Open language-specific specialty feeds and department pages.